Disappointing results mean MLN 8237 (alisertib) discontinued in T-Cell Lymphoma-Takeda
Takeda Pharmaceuticals has announced that it has decided to discontinue the Phase III trial of MLN 8237 (alisertib) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following the results of a pre-specified interim analysis that indicated the study is unlikely to meet the primary endpoint of superior progression-free survival (PFS) over the standard-of-care in this treatment setting.
Takeda continues to investigate the utility of alisertib in small cell lung cancer (SCLC). Patients enrolled in the Phase 3 PTCL clinical trial who are being treated with alisertib may continue treatment if they are considered to be benefitting from treatment, and no safety concerns are present.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.